Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Phair Pricing Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support reintroduction of Restoring Patients Voice Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (P.L. 115-182). Advocate for the continued funding of Community Health Centers.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2019 · fourth_quarter · Q4
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs. (S.1089/H.R.1922, Restoring Access to Medication Act)
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Source: Senate LDA
Phair Pricing Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Phair Pricing Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Phair Pricing Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Phair Pricing Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Phair Pricing Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Phair Pricing Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act Support S. 657 Drug Price Transparency Act
Phair Pricing Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Prescription Drug Price Transparency Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Prescription Drug Price Transparency Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Prescription Drug Price Transparency Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support reintroduction of Restoring Patients Voice Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (P.L. 115-182). Advocate for the continued funding of Community Health Centers.
Prescription Drug Price Transparency Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Prescription Drug Price Transparency Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act Support S. 657 Drug Price Transparency Act
Prescription Drug Price Transparency Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Prescription Drug Price Transparency Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Prescription Drug Price Transparency Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Consolidated Appropriations Act, 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740; H.R. 1865). Advocate for funding for teledermatology devices at Indian Health Services Health Centers (H.R. 3052; S. 2580; H.R. 1865). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790; H.R. 1865). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474; H.R. 1158). Advocate for the importance of sunscreen use and messaging by the Food and Drug Administration as they communicate to the public regarding the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products (H.R. 3055, S. 2522; H.R. 1865). Advocate for the importance of sunscreen use in policies regarding the study of environmental impact of sunscreen ingredients by the Environmental Protection Agency and/or the National Academy of Sciences (H.R. 3052. S. 2580; H.R. 1865).
Consolidated Appropriations Act, 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740; H.R. 1865). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790; H.R. 1865). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474; H.R. 1158).
Ensuring Lasting Smiles Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support reintroduction of Restoring Patients Voice Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (P.L. 115-182). Advocate for the continued funding of Community Health Centers.
Ensuring Lasting Smiles Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Ensuring Lasting Smiles Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Ensuring Lasting Smiles Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Protecting Consumer Access to Generic Drugs Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Protecting Consumer Access to Generic Drugs Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
REDI Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
REDI Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
REDI Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Defending Our National Marine Sanctuaries from Damaging Chemicals Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587; H.R. 3052; S. 2580; H.R. 1865)
Defending Our National Marine Sanctuaries from Damaging Chemicals Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587; H.R. 3052; S. 2580)
Defending Our National Marine Sanctuaries from Damaging Chemicals Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587).
Further Consolidated Appropriations Act, 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587; H.R. 3052; S. 2580; H.R. 1865)
Further Consolidated Appropriations Act, 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740; H.R. 1865). Advocate for funding for teledermatology devices at Indian Health Services Health Centers (H.R. 3052; S. 2580; H.R. 1865). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790; H.R. 1865). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474; H.R. 1158). Advocate for the importance of sunscreen use and messaging by the Food and Drug Administration as they communicate to the public regarding the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products (H.R. 3055, S. 2522; H.R. 1865). Advocate for the importance of sunscreen use in policies regarding the study of environmental impact of sunscreen ingredients by the Environmental Protection Agency and/or the National Academy of Sciences (H.R. 3052. S. 2580; H.R. 1865).
Further Consolidated Appropriations Act, 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740; H.R. 1865). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790; H.R. 1865). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474; H.R. 1158).
Restoring Access to Medication Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs. (S.1089/H.R.1922, Restoring Access to Medication Act)
Restoring Access to Medication Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs. (S.1089/H.R.1922, Restoring Access to Medication Act)
Restoring Access to Medication Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.1085/H.R.1922, Restoring Access to Medication Act).
Preserving Patient Access to Compounded Medications Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Preserving Patient Access to Compounded Medications Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Preserving Patient Access to Compounded Medications Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support reintroduction of Restoring Patients Voice Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (P.L. 115-182). Advocate for the continued funding of Community Health Centers.
Preserving Patient Access to Compounded Medications Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Preserving Patient Access to Compounded Medications Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Preserving Patient Access to Compounded Medications Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act Support S. 657 Drug Price Transparency Act
Preserving Patient Access to Compounded Medications Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Preserving Patient Access to Compounded Medications Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
SPIKE Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
SPIKE Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
SPIKE Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Global Brain Health Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Global Brain Health Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Global Brain Health Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
PIMA of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Oppose H.R. 2143, Promoting Integrity in Medicare Act (PIMA) of 2019. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019 Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate against a Medicare physician payment freeze beginning in January 2020 that was created under MACRA (P.L. 114-110) and the creation of the Quality Payment Program. Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Support H.R. 3302, Keep Physicians Serving Patients Act. Advocate in support of nomination of Michael Bigby, MD, to serve as Commissioner on the Medicare Payment Advisory Commission.
PIMA of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Oppose H.R. 2143, Promoting Integrity in Medicare Act (PIMA) of 2019. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019 Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Advocate against a Medicare physician payment freeze beginning in January 2020 that was created under MACRA (P.L. 114-110) and the creation of the Quality Payment Program. Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Support H.R. 3302, Keep Physicians Serving Patients Act.
PIMA of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Oppose H.R. 2143, Promoting Integrity in Medicare Act (PIMA) of 2019. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019 Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Advocate against a Medicare physician payment freeze beginning in January 2020 that was created under MACRA (P.L. 114-110) and the creation of the Quality Payment Program. Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Support H.R. 3302, Keep Physicians Serving Patients Act. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Medicare Care Coordination Improvement Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019 Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Advocate in support of nomination of Michael Bigby, MD, to serve as Commissioner on the Medicare Payment Advisory Commission.
Medicare Care Coordination Improvement Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Oppose H.R. 2143, Promoting Integrity in Medicare Act (PIMA) of 2019. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019 Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Advocate against a Medicare physician payment freeze beginning in January 2020 that was created under MACRA (P.L. 114-110) and the creation of the Quality Payment Program. Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Support H.R. 3302, Keep Physicians Serving Patients Act.
Medicare Care Coordination Improvement Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Oppose H.R. 2143, Promoting Integrity in Medicare Act (PIMA) of 2019. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019 Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate against a Medicare physician payment freeze beginning in January 2020 that was created under MACRA (P.L. 114-110) and the creation of the Quality Payment Program. Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Support H.R. 3302, Keep Physicians Serving Patients Act. Advocate in support of nomination of Michael Bigby, MD, to serve as Commissioner on the Medicare Payment Advisory Commission.
Medicare Care Coordination Improvement Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Oppose H.R. 2143, Promoting Integrity in Medicare Act (PIMA) of 2019. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019 Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Advocate against a Medicare physician payment freeze beginning in January 2020 that was created under MACRA (P.L. 114-110) and the creation of the Quality Payment Program. Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Support H.R. 3302, Keep Physicians Serving Patients Act. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
More Efficient Tools to Realize Information for Consumers Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
More Efficient Tools to Realize Information for Consumers Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
More Efficient Tools to Realize Information for Consumers Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
REACH Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
REACH Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Preserve Access to Affordable Generics and Biosimilars Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Preserve Access to Affordable Generics and Biosimilars Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Preserve Access to Affordable Generics and Biosimilars Act
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Prescription Pricing for the People Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Prescription Pricing for the People Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Prescription Pricing for the People Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Prescription Pricing for the People Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Prescription Pricing for the People Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Prescription Pricing for the People Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
National Defense Authorization Act for Fiscal Year 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740; H.R. 1865). Advocate for funding for teledermatology devices at Indian Health Services Health Centers (H.R. 3052; S. 2580; H.R. 1865). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790; H.R. 1865). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474; H.R. 1158). Advocate for the importance of sunscreen use and messaging by the Food and Drug Administration as they communicate to the public regarding the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products (H.R. 3055, S. 2522; H.R. 1865). Advocate for the importance of sunscreen use in policies regarding the study of environmental impact of sunscreen ingredients by the Environmental Protection Agency and/or the National Academy of Sciences (H.R. 3052. S. 2580; H.R. 1865).
National Defense Authorization Act for Fiscal Year 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740). Advocate for funding for teledermatology devices at Indian Health Services Health Centers (H.R. 3052; S. 2580). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474). Advocate for the importance of sunscreen use and messaging by the Food and Drug Administration as they communicate to the public regarding the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products (H.R. 3055, S. 2522). Advocate for the importance of sunscreen use in policies regarding the study of environmental impact of sunscreen ingredients by the Environmental Protection Agency and/or the National Academy of Sciences (H.R. 3052. S. 2580).
National Defense Authorization Act for Fiscal Year 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474).
National Defense Authorization Act for Fiscal Year 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740; H.R. 1865). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790; H.R. 1865). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474; H.R. 1158).
National Defense Authorization Act for Fiscal Year 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740). Advocate for the study of indoor tanning in qualified physical fitness centers (H.R. 2740). Advocate for funding for teledermatology devices at Indian Health Services Health Centers (H.R. 3052). Advocate for the Health Resources and Services Administration to study specialty physician shortages (H.R. 2740). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740). Advocate for the importance of sunscreen use and messaging by the Food and Drug Administration as they communicate to the public regarding the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products (H.R. 2740). Advocate for the importance of sunscreen use in policies regarding the study of environmental impact of sunscreen ingredients by the Environmental Protection Agency and/or the National Academy of Sciences (H.R. 2740).
National Defense Authorization Act for Fiscal Year 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740). Advocate for the Health Resources and Services Administration to study specialty physician shortages (H.R. 2740). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740).
Reef Safe Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587; H.R. 3052; S. 2580)
Reef Safe Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587).
Reef Safe Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587; H.R. 3052; S. 2580; H.R. 1865)
Oxybenzone and Octinoxate Impact Study Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587; H.R. 3052; S. 2580; H.R. 1865)
Oxybenzone and Octinoxate Impact Study Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587; H.R. 3052; S. 2580)
Oxybenzone and Octinoxate Impact Study Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587).
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support reintroduction of Restoring Patients Voice Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (P.L. 115-182). Advocate for the continued funding of Community Health Centers.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895). Support H.R. 4575, Improving Provider Directories Act, which would require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act Support S. 657 Drug Price Transparency Act
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740). Advocate for the Health Resources and Services Administration to study specialty physician shortages (H.R. 2740). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740).
Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020
Client: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION · Firm: AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740). Advocate for funding for teledermatology devices at Indian Health Services Health Centers (H.R. 3052; S. 2580). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474). Advocate for the importance of sunscreen use and messaging by the Food and Drug Administration as they communicate to the public regarding the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products (H.R. 3055, S. 2522). Advocate for the importance of sunscreen use in policies regarding the study of environmental impact of sunscreen ingredients by the Environmental Protection Agency and/or the National Academy of Sciences (H.R. 3052. S. 2580).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740; H.R. 1865). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790; H.R. 1865). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474; H.R. 1158).
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587; H.R. 3052; S. 2580; H.R. 1865)
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program, included in the VA MISSION Act (Public Law No: 115-182).
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740; H.R. 1865). Advocate for funding for teledermatology devices at Indian Health Services Health Centers (H.R. 3052; S. 2580; H.R. 1865). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790; H.R. 1865). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474; H.R. 1158). Advocate for the importance of sunscreen use and messaging by the Food and Drug Administration as they communicate to the public regarding the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products (H.R. 3055, S. 2522; H.R. 1865). Advocate for the importance of sunscreen use in policies regarding the study of environmental impact of sunscreen ingredients by the Environmental Protection Agency and/or the National Academy of Sciences (H.R. 3052. S. 2580; H.R. 1865).
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Oppose H.R. 2143, Promoting Integrity in Medicare Act (PIMA) of 2019. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019 Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Advocate against a Medicare physician payment freeze beginning in January 2020 that was created under MACRA (P.L. 114-110) and the creation of the Quality Payment Program. Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Support H.R. 3302, Keep Physicians Serving Patients Act. Support the Creating Opportunities Now for Necessary and Effect Care Technologies (CONNECT) for Health Act of 2019 (S. 2741/H.R. 4932), which would increase access to telehealth services.
Filing targets: Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2019 · third_quarter · Q3
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587; H.R. 3052; S. 2580)
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740). Advocate for funding for teledermatology devices at Indian Health Services Health Centers (H.R. 3052; S. 2580). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474). Advocate for the importance of sunscreen use and messaging by the Food and Drug Administration as they communicate to the public regarding the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products (H.R. 3055, S. 2522). Advocate for the importance of sunscreen use in policies regarding the study of environmental impact of sunscreen ingredients by the Environmental Protection Agency and/or the National Academy of Sciences (H.R. 3052. S. 2580).
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Oppose H.R. 2143, Promoting Integrity in Medicare Act (PIMA) of 2019. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019 Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Advocate against a Medicare physician payment freeze beginning in January 2020 that was created under MACRA (P.L. 114-110) and the creation of the Quality Payment Program. Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Support H.R. 3302, Keep Physicians Serving Patients Act.
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program, included in the VA MISSION Act (Public Law No: 115-182).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740, S. 2474).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077/S. 2546, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 3107, Seniors Timely Access to Care Act Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support S. 2443 Investment in Tomorrows Pediatric Health Care Workforce Act Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection. In the context of legislation to address surprise medical bills, advocate for an independent dispute resolution (IDR) process to resolve disputes between payers and physicians and against provisions that would set out-of-network reimbursement rates at a benchmark level. (H.R. 2328, H.R. 3502, S. 1531, S. 1895)
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs. (S.1089/H.R.1922, Restoring Access to Medication Act)
Filing targets: Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2019 · second_quarter · Q2
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for expansion of telemedicine services under Medicare and increased reimbursement for such services. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Oppose H.R. 2143, Promoting Integrity in Medicare Act (PIMA) of 2019. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019 Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate against a Medicare physician payment freeze beginning in January 2020 that was created under MACRA (P.L. 114-110) and the creation of the Quality Payment Program. Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Support H.R. 3302, Keep Physicians Serving Patients Act. Advocate in support of nomination of Michael Bigby, MD, to serve as Commissioner on the Medicare Payment Advisory Commission.
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.1085/H.R.1922, Restoring Access to Medication Act).
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740). Advocate for the Health Resources and Services Administration to study specialty physician shortages (H.R. 2740). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740).
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program, included in the VA MISSION Act (Public Law No: 115-182).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act. H.R. 2115, Public Disclosure of Drug Discounts Act H.R. 2376/S. 1227, Prescription Pricing for the People Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act. Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products.
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R. 2740). Advocate for the study of indoor tanning in qualified physical fitness centers (H.R. 2740). Advocate for funding for teledermatology devices at Indian Health Services Health Centers (H.R. 3052). Advocate for the Health Resources and Services Administration to study specialty physician shortages (H.R. 2740). Advocate for medical research funding in the National Defense Authorization Act (H.R. 2500, S. 1790). Advocate for dedicated funding for Melanoma research in the Congressional Directed Medical Research Programs in the FY 20 Department of Defense Appropriations bill (H.R. 2968, H.R. 2740). Advocate for the importance of sunscreen use and messaging by the Food and Drug Administration as they communicate to the public regarding the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products (H.R. 2740). Advocate for the importance of sunscreen use in policies regarding the study of environmental impact of sunscreen ingredients by the Environmental Protection Agency and/or the National Academy of Sciences (H.R. 2740).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Safe Step Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support H.R. 2375/S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1499, Protecting Consumer Access to Generic Drugs Act Support H.R. 2296/S. 1391, Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2069, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act. Support H.R. 2115, Public Disclosure of Drug Discounts Act Support H.R. 2376/S. 1227, Prescription Pricing for the People Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Support H.R. 1554, Resident Education Deferred Interest (REDI) Act. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (Public Law 115-182). Advocate for the continued and increased funding of Community Health Centers. Lobby members of Congress to cosponsor H. Res. 323, which would support state, local, and community initiatives to encourage parents, teachers, camp counselors, and childcare professionals to take measures to prevent sunburns in the minors they care for, and would express the sense of the House of Representatives that state, local, and community entities should continue to support efforts to curb the incidences of skin cancer beginning with childhood skin protection.
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients, including the effect on coral reef, and any directive calling for a study by the Environmental Protection Agency and/or the National Academy of Sciences. (H.R. 1834; H.R. S. 1371, H.R. 2588; S. 1375, H.R. 2587).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2019 · first_quarter · Q1
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. Advocate for the study of indoor tanning in qualified physical fitness centers. Advocate for funding for tele-dermatology devices at Indian Health Services Health Centers. Advocate for the Health Resources and Services Administration to study specialty physician shortages.
Advocate for the importance of sunscreen use in policies regarding the environmental impact of sunscreen ingredients.
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.1085/H.R.1922, Restoring Access to Medication Act and H.R. 6199, the Restoring Access to Medication and Modernizing Health Savings Accounts Act of 2018.)
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support reintroduction of Restoring Patients Voice Act. Support H.R. 1035, Prescription Drug Price Transparency Act. Support H.R. 985, Fair Access for Safe and Timely Generics Act. Support H.R. 965/S. 340, Creating and Restoring Equal Access to Equivalent Samples Act. Support reintroduction of Patients Access to Treatments Act. Support S. 476, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 1034/S. 640, Phair Pricing Act. Support S. 657, Drug Price Transparency Act Support H.R. 938, BLOCKING Act Support S. 64, Preserve Access to Affordable Generics & Biosimilars Act Support H.R. 1379/S. 560, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support sunscreen related provisions in H.R. 269, the Pandemic & All Hazards Preparedness & Advancing Innovation Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for access to dermatological procedures for veterans through the VA MISSION Act (P.L. 115-182). Advocate for the continued funding of Community Health Centers.
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program, included in the VA MISSION Act (Public Law No: 115-182).
Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2020 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. Advocate for the study of indoor tanning in qualified physical fitness centers. Advocate for funding for tele-dermatology devices at Indian Health Services Health Centers. Advocate for the Health Resources and Services Administration to study specialty physician shortages.
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 1959, Preserving Patient Access to Compounded Medications Act. Support H.R. 1035, Prescription Drug Price Transparency Act Support S. 476, C-THRU Act. Support H.R. 1034/S. 640, Phair Pricing Act Support sunscreen related provisions in H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act Support S. 657 Drug Price Transparency Act
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 2282/S.966 Medicare Care Coordination Improvement Act of 2019 Advocate for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Advocate in support of nomination of Michael Bigby, MD, to serve as Commissioner on the Medicare Payment Advisory Commission.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2018 · fourth_quarter · Q4
Advocate for legislation to enact medical liability reforms. Support H.R. 1704, Accessible Care by Curbing Excessive lawSuitS (ACCESS) Act. Support H.R. 1215, Protecting Access to Care Act. Support H.R. 1876, Good Samaritans Health Professionals Act
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support H. Res. 282 to encourage proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Restoring Patients Voice Act. Support H.R. 1316, Prescription Drug Price Transparency Act. Support H.R. 2051, Fair Access for Safe and Timely Generics Act. Support H.R. 2212/S. 974, Creating and Restoring Equal Access to Equivalent Samples Act. Support H.R. 2999, Patients Access to Treatments Act. Support H.R. 3928, the Truth in Healthcare Marketing Act of 2017. Support S. 637, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support H.R. 5958, Phair Pricing Act. Support H.R. 6689/S. 3368, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 4841/H.R. 5773/Section 6062 of H.R. 6 (SUPPORT for Patients & Communities Act), Standardizing Electronic Prior Authorization for Safe Prescribing Act and S. 2908, Electronic Prior Authorization in Medicare Part D Act. Support sunscreen related provisions in S. 2315, OTC Drug Safety, Innovation & Reform Act/H.R. 5333, OTC Monograph Safety, Innovation, & Reform Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for access to dermatological procedures for veterans through the Veterans Choice Program. Advocate for the continued funding of Community Health Centers. Advocate against including physician advocacy and membership organization in the Physician Payment Sunshine Act requirements as originally included in S. 3000; advocated against inclusion in S. Amendment 4013 to H.R. 6.
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Support provisions to allow Medicare Advantage plans to include telehealth as a benefit. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 4206/S.2051 Medicare Care Coordination Improvement Act of 2017 Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Oppose elimination of a Merit-Based Incentive Payment System. Advocate allowing further appeals process within the Quality Payment Program. Advocate against H.R. 2066, Promoting Integrity in Medicare Act of 2017. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 4841/H.R. 5773/Section 6062 of H.R. 6 (SUPPORT for Patients & Communities Act), Standardizing Electronic Prior Authorization for Safe Prescribing Act and S. 2908, Electronic Prior Authorization in Medicare Part D Act Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Lobby Congress to urge CMS to withdraw evaluation and management (E/M) coding and payment proposals, including the Modifier 25 proposal or what is also sometimes referred to as the multiple procedure payment reduction (MPPR), from 2019 Medicare Physician Fee Schedule. Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs. Lobby Congress to urge CMS to maintain oversight for correct implementation and calculation of QCDR measures and to ensure QCDRs intellectual property is protected. Lobby Congress to urge CMS to pause implementation of a new policy that allows Medicare Advantage plans to implement step therapy protocols, and to work with stakeholders to find an alternative solution.
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268). Support maintaining the Prevention and Public Health Fund (PPHF).
Support legislation, such as, S. 1615/ H.R. 3440 DREAM Act, which would enable those individuals eligible with Deferred Action for Childhood Arrivals status are able to continue their employment, education, training, and research.
Advocate against H.R. 1150, the Tanning Tax Repeal Act of 2017, and S. 2600, the Tanning Tax Repeal act of 2018, to repeal excise tax on indoor tanning services. Advocate against the inclusion of repealing the tax on indoor tanning services in tax-related legislation (H.R. 3798, the Save Americas Workers Act of 2017; and H.R. 6760, The Protecting Family and Small Business Tax Cuts Act of 2018). Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.85/H.R. 394, Restoring Access to Medication Act and H.R. 6199, the Restoring Access to Medication and Modernizing Health Savings Accounts Act of 2018.)
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program, included in the VA MISSION Act (Public Law No: 115-182).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 1316, Prescription Drug Price Transparency Act Support S. 637, C-THRU Act. Support H.R. 5958, Phair Pricing Act Support sunscreen related provisions in S. 2315, OTC Drug Safety, Innovation & Reform Act/H.R. 5333, OTC Monograph Safety, Innovation, & Reform Act; provisions also included in H.R. 7328, Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2018 · third_quarter · Q3
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration in FY19 Labor/HHS/Education Appropriations (H.R. 6470/S. 3158; H.R. 6157). Advocate for The National Hansens Disease Program funding in FY19 Labor/HHS/Education Appropriations (H.R. 6470, S. 3158; H.R. 6157). Support funding for Directed Medical Research Programs (CDMRP) at the Department of Defense (DoD) in the Fiscal Year 2019 (FY19) Defense Appropriations bill (H.R. 6157, S. 3159). Support dedicated Melanoma research funding, outside of the Peer-Reviewed Cancer Research Program, at the DoD (H.R. 6157). Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268). Support maintaining the Prevention and Public Health Fund (PPHF).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support H. Res. 282 to encourage proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Restoring Patients Voice Act. Support H.R. 1316, Prescription Drug Price Transparency Act. Support H.R. 2051, Fair Access for Safe and Timely Generics Act. Support H.R. 2212/S. 974, Creating and Restoring Equal Access to Equivalent Samples Act. Support H.R. 2999, Patients Access to Treatments Act. Support H.R. 3928, the Truth in Healthcare Marketing Act of 2017. Support S. 637, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act. Support S. 2553, Know the Lowest Prices Act. Support S. 2554, Patient Right to Know Drug Prices Act. Support H.R. 5958, Phair Pricing Act. Support H.R. 5343, Prescription Transparency Act. Support H.R. 6689/S. 3368, Ensuring Lasting Smiles Act. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 4841/H.R. 5773/Section 6062 of H.R. 6 (SUPPORT for Patients & Communities Act), Standardizing Electronic Prior Authorization for Safe Prescribing Act and S. 2908, Electronic Prior Authorization in Medicare Part D Act. Support sunscreen related provisions in S. 2315, OTC Drug Safety, Innovation & Reform Act/H.R. 5333, OTC Monograph Safety, Innovation, & Reform Act. Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for access to dermatological procedures for veterans through the Veterans Choice Program. Advocate for the continued funding of Community Health Centers. Advocate against including physician advocacy and membership organization in the Physician Payment Sunshine Act requirements as originally included in S. 3000; advocated against inclusion in S. Amendment 4013 to H.R. 6.
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2018 · second_quarter · Q2
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration in FY19 Labor/HHS/Education Appropriations (House Bill TBD/S. 3158). Advocate for The National Hansens Disease Program funding in FY19 Labor/HHS/Education Appropriations (House Bill TBD, S. 3158). Support funding for Directed Medical Research Programs (CDMRP) at the Department of Defense (DoD) in the Fiscal Year 2019 (FY19) Defense Appropriations bill (H.R. 6157, S. 3159). Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 198 Labor/HHS/Education Appropriations, H.R. 3358/S. 31581771, and FY 198 Agriculture Appropriations bills, H.R. 59613268/S. 12976603).
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2018 · first_quarter · 1A
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 36268/S. 1603). Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268). Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration in FY19 Labor/HHS/Education Appropriations (Bill TBD) Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (H.R. 1628, Consolidated Appropriations Act, 2018) Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS) in the Bipartisan Budget Act of 2018, HR. 1892. Advocate for the expansion of telehealth coverage under Medicare Advantage Plan B, beginning in 2020 in the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for the repeal of the Independent Payment Advisory Board (IPAB) as part of the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for the elimination of the requirement that make electronic health record (EHR) meaningful use (MU) standards more stringent over time as part of the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for funding the Community Health Center Fund in 2018 and 2019 in the Bipartisan Budget Act of 2018, H.R. 1892. Oppose extension of the Medicare misvalued codes policy as part of the Bipartisan Budget Act of 2018, H.R. 1892. Oppose extension of 2 percent sequestration cuts to Medicare through 2027 as part of the Bipartisan Budget Act of 2018, H.R. 1892. Support maintaining the Prevention and Public Health Fund (PPHF); opposed provisions to reducing PPHF in H.R.1892.
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2018 · first_quarter · Q1
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 36268/S. 1603). Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268). Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration in FY19 Labor/HHS/Education Appropriations (Bill TBD) Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (H.R. 1628, Consolidated Appropriations Act, 2018) Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS) in the Bipartisan Budget Act of 2018, HR. 1892. Advocate for the expansion of telehealth coverage under Medicare Advantage Plan B, beginning in 2020 in the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for the repeal of the Independent Payment Advisory Board (IPAB) as part of the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for the elimination of the requirement that make electronic health record (EHR) meaningful use (MU) standards more stringent over time as part of the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for funding the Community Health Center Fund in 2018 and 2019 in the Bipartisan Budget Act of 2018, H.R. 1892. Oppose extension of the Medicare misvalued codes policy as part of the Bipartisan Budget Act of 2018, H.R. 1892. Oppose extension of 2 percent sequestration cuts to Medicare through 2027 as part of the Bipartisan Budget Act of 2018, H.R. 1892. Support maintaining the Prevention and Public Health Fund (PPHF); opposed provisions to reducing PPHF in H.R.1892.
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2017 · fourth_quarter · Q4
Advocate for legislation to enact medical liability reforms. Support H.R. 1704, Accessible Care by Curbing Excessive lawSuitS (ACCESS) Act. Support H.R. 1215, Protecting Access to Care Act.
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support H. Res. 282 to encourage proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Restoring Patients Voice Act. Support H.R. 1316, Prescription Drug Price Transparency Act. Support H.R. 2051, Fair Access for Safe and Timely Generics Act. Support H.R. 2212/S. 974, Creating and Restoring Equal Access to Equivalent Samples Act. Support H.R. 2999, Patients Access to Treatments Act. Support H.R. 3928, the Truth in Healthcare Marketing Act of 2017. Support S. 637, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for reform of insurers prior authorization practices. Advocate for access to dermatological procedures for veterans through the Veterans Choice Program. Advocate for the continued funding of Community Health Centers
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2017 · third_quarter · Q3
Advocate against the repeal of the tanning tax provision under the Better Care Reconciliation Act of 2017 (H.R. 1628). Advocate against H.R. 1150, the Tanning Tax Repeal Act of 2017, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.85/H.R. 394, Restoring Access to Medication Act).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for the sense of Congress that states should expand access to sun safety products and practices. Lobby members of Congress to support H. Res. 282 to encourage proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Advocate for generic drug approval reform in H.R. 2430 /S. 934, FDA Reauthorization Act. Support H.R. 749, the Lower Drug Costs through Competition Act. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Restoring Patients Voice Act. Support H.R. 1316, Prescription Drug Price Transparency Act. Support H.R. 2051, Fair Access for Safe and Timely Generics Act. Support H.R. 2212/S. 974, Creating and Restoring Equal Access to Equivalent Samples Act. Support H.R. 2999, Patients Access to Treatments Act. Support S. 637, C-THRU Act. Support S. 297, Increasing Competition in Pharmaceuticals Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for reform of insurers prior authorization practices. Advocate for access to dermatological procedures for veterans through the Veterans Choice Program.
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2017 · second_quarter · Q2
Lobby members of the House to write to FDA regarding the agencys final guidance document on office-use compounding. Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act, intended to protect and preserve the in-office use of compounded pharmaceuticals without a patient prescription. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Advocate for the sense of Congress that states should expand access to sun safety products and practices. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Lobby members of Congress to support H. Res. 282 to encourage proper sun safety practices for youth under care of schools and camps. Support, S. Res. 182, a resolution designating May 2017 as "Melanoma Awareness Month. Advocate for generic drug approval reform in H.R. 2430/S. S.934, FDA Reauthorization Act. Support H.R. 749, the Lower Drug Costs through Competition Act. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Restoring Patients Voice Act. Support H.R. 1316, Prescription Drug Price Transparency Act. Support H.R. 2051, Fair Access for Safe and Timely Generics Act. Support H.R. 2212/S. 974, Creating and Restoring Equal Access to Equivalent Samples Act. Support H.R. 2999, Patients Access to Treatments Act. Support S. 637, C-THRU Act. Support S. 297, Increasing Competition in Pharmaceuticals Act.
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2017 · first_quarter · Q1
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Support legislation to eliminate the Independent Payment Advisory Board (H.R. 849, Protecting Seniors Access to Medicare Act, H.J. Res. 51, S.251, Protecting Medicare from Executive Action Act, S. 260, Protecting Seniors Access to Medicare Act, S.J. Res. 16 and S.J. Res. 17) Advocate for increased funding and reforms to Graduate Medical Education. Lobby members of Congress regarding improvements to Health Information Technology implementation. Lobby members of Congress regarding issues related to telemedicine and Medicare reimbursement . Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act, including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS).
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2016 · fourth_quarter · Q4
Advocate for improved access to specialty drugs for patients with chronic conditions (H.R. 1600, Patients' Access to Treatments Act of 2015). Lobby members of House and Senate to write to FDA regarding the agencys draft guidance document on office-use compounding. Support S. 2615, the Increasing Competition in Pharmaceuticals Act. Support H.R. 4784, the Lower Drug Costs through Competition Act. Lobby members of Congress to join the Congressional Skin Cancer Caucus. Lobby Congress to provide oversight of implementation of Public Law 113-54, the Drug Quality and Security Act, and to protect and preserve the in-office use of compounded pharmaceuticals without a patient prescription. Lobby in support of FDAs proposed rule to restrict indoor tanning for youth under 18. Lobby Congress on issues related to telemedicine. Advocate for increased price transparency for drugs and tools to help lower costs. Advocate for increased funding and reforms to Graduate Medical Education including Ensuring Childrens Access to Specialty Care Act (H.R. 1859/S. 2782). Oppose paragraph d, Location of Care in Section 704, Enhancement of Use of Telehealth Services in Military Health System" in the Senate-passed version of S. 2943, the National Defense Authorization Act for Fiscal Year 2017. Lobby members of Congress to support H. Res. 854 to encourage proper sun safety practices for youth under care of schools and camps. Support legislation to study online learning collaboratives and the impact they have on the health care systems (H.R. 5395/S. 2873 The Expanding Capacity for Health Outcomes Act aka ECHO Act).
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2016 · third_quarter · Q3
Advocate for improved access to specialty drugs for patients with chronic conditions (H.R. 1600, Patients' Access to Treatments Act of 2015). Lobby members of House and Senate to write to FDA regarding the agencys draft guidance document on office-use compounding. Support S. 2615, the Increasing Competition in Pharmaceuticals Act. Support H.R. 4784, the Lower Drug Costs through Competition Act. Lobby members of Congress to join the Congressional Skin Cancer Caucus. Lobby Congress to provide oversight of implementation of Public Law 113-54, the Drug Quality and Security Act, and to protect and preserve the in-office use of compounded pharmaceuticals without a patient prescription. Lobby in support of FDA proposed rule to restrict indoor tanning for youth under 18. Lobby Congress on issues related to telemedicine. Support legislation to establish a federal standard for the provision of telemedicine (H.R. 691, the Telehealth Modernization Act). Support the review of online learning collaboratives and their integration into health care systems (H.R. 5395/S. 2873 The Expanding Capacity for Health Outcomes Act) Oppose S.2175, Department of Veterans Affairs Provider Equity Act. Advocate for increased price transparency for drugs and tools to help lower costs. Advocate for increased funding and reforms to Graduate Medical Education including Ensuring Childrens Access to Specialty Care Act (H.R. 1859/S. 2782). Oppose paragraph d, Location of Care, in Section 705, "Enhancement of Use of Telehealth Services in Military Health System," in S. 2943, the National Defense Authorization Act for Fiscal Year 2017. Lobby members of Congress to support H. Res 854 to encourage proper sun safety practices for youth under care of schools and camps.
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2016 · second_quarter · Q2
Support H.R. 6, the 21st Century Cures Act to strengthen and improve the discovery, development and delivery of treatments and cures Advocate for NIH and FDA reforms in the Innovation for Healthier Americans initiative. Advocate for medical research, education and prevention funding at the National Institutes of Health, National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality under the Labor, Health and Human Services, and Education Appropriations legislation (S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017) Advocate for maintain funding as well as application processes in the Department of Defense medical research programs. Support legislation to adjust discretionary spending caps for biomedical research (S. 318/H.R. 531, Accelerating Biomedical Research Act; S. 289, American Cures Act).
AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION via AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION
2016 · first_quarter · Q1
Advocate against H.R. 2698, the Tanning Tax Repeal Act of 2015, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S. 709, H.R. 1270, Restoring Access to Medication Act).
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage and health insurance exchange networks (S. 2392 / H.R. 4227, the Medicare Advantage Bill of Rights Act of 2015). Support legislation to eliminate the Independent Payment Advisory Board (S.141/ H.R. 1190, Protecting Seniors' Access to Medicare Act of 2015). Advocate on issues related to waste, fraud and abuse in Medicare Advocate for increased funding and reforms to Graduate Medical Education. Lobby Congress on improvements to Health Information Technology implementation. Lobby Congress in opposition to repeal of the in-office ancillary and physician services exception for anatomic pathology services. Lobby Congress on issues related to telemedicine and Medicare reimbursement. Advocate on use and availability of health care data. Lobby in support of legislation to provide more flexibility in the Meaningful Use program (H.R. 3309, the Further Flexibility in HIT Reporting and Advancing Interoperability (Flex IT 2) Act) Advocate for EHR interoperability and enhancements to the federal certification system for health information technology (S. 2141, Transparent Ratings on Usability & Security to Transform Technology Act of 2015 and S.2511, Improving Health Information Technology Act). Lobby in support of legislation to require the Secretary of Health and Human Services to issue guidance on the application of the Common Rule to clinical data registries (H.R. 965, Facilitating Participation in Clinical Data Registries Act of 2015). Support legislation to improve transparency and due process in the Medicare RAC audit and appeals process (H.R. 2568, Fair Medical Audits Act). Support legislation to reduce Medicare fraud and improve access to Death Master File, S. 1073, the Stopping Improper Payments to Deceased People Act. Advocate for improving disease management and care coordination for patients with chronic diseases Support preservation of the In Offices Ancillary Services Exemption under Stark Law regarding physician self-referral; respond to request for comment regarding possible changes to Stark Law.
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program, included in the VA MISSION Act (Public Law No: 115-182).
Advocate against H.R. 1150, the Tanning Tax Repeal Act of 2017, and S. 2600, the Tanning Tax Repeal act of 2018, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.85/H.R. 394, Restoring Access to Medication Act and H.R. 6199, the Restoring Access to Medication and Modernizing Health Savings Accounts Act of 2018. Advocate against the inclusion of the repeal of the excise tax on indoor tanning services in the Save American Workers Act (H.R. 3798).
Support legislation, such as, S. 1615/ H.R. 3440 DREAM Act, which would enable those individuals eligible with Deferred Action for Childhood Arrivals status are able to continue their employment, education, training, and research.
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Support provisions to allow Medicare Advantage plans to include telehealth as a benefit. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 4206/S.2051 Medicare Care Coordination Improvement Act of 2017 Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Oppose elimination of a Merit-Based Incentive Payment System. Advocate allowing further appeals process within the Quality Payment Program. Advocate against H.R. 2066, Promoting Integrity in Medicare Act of 2017. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 4841/H.R. 5773/Section 6062 of H.R. 6 (SUPPORT for Patients & Communities Act), Standardizing Electronic Prior Authorization for Safe Prescribing Act and S. 2908, Electronic Prior Authorization in Medicare Part D Act Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Support S. 2553, Know the Lowest Price Act. Lobby Congress to urge CMS to withdraw evaluation and management (E/M) coding and payment proposals, including the Modifier 25 proposal or what is also sometimes referred to as the multiple procedure payment reduction (MPPR), from 2019 Medicare Physician Fee Schedule. Lobby Congress to urge CMS to strengthen Qualified Clinical Data Registries (QCDRs) by removing barriers that restrict access to data from EHRs.
Advocate for legislation to enact medical liability reforms. Support H.R. 1704, Accessible Care by Curbing Excessive lawSuitS (ACCESS) Act. Support H.R. 1215, Protecting Access to Care Act. Support H.R. 1876, Good Samaritans Health Professionals Act
Support funding for Directed Medical Research Programs (CDMRP) at the Department of Defense (DoD) in the Fiscal Year 2019 (FY19) Defense Appropriations bill (H.R. 6157, S. 3159). Support dedicated Melanoma research funding, outside of the Peer-Reviewed Cancer Research Program, at the DoD (H.R. 6157).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 1316, Prescription Drug Price Transparency Act Support S. 637, C-THRU Act. Support S. 2553, Know the Lowest Price Act. Support S. 2554, Patient Right to Know Drug Prices Act. Support H.R. 5958, Phair Pricing Act. Support H.R. 5343, Prescription Transparency Act. Support sunscreen related provisions in S. 2315, OTC Drug Safety, Innovation & Reform Act/H.R. 5333, OTC Monograph Safety, Innovation, & Reform Act.
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration in FY19 Labor/HHS/Education Appropriations (H.R. 6470/S. 3158; H.R. 6157). Advocate for The National Hansens Disease Program funding in FY19 Labor/HHS/Education Appropriations (H.R. 6470, S. 3158; H.R. 6157). Support funding for Directed Medical Research Programs (CDMRP) at the Department of Defense (DoD) in the Fiscal Year 2019 (FY19) Defense Appropriations bill (H.R. 6157, S. 3159). Support dedicated Melanoma research funding, outside of the Peer-Reviewed Cancer Research Program, at the DoD (H.R. 6157).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 19Labor/HHS/Education Appropriations, S. 3158, and FY 19 Agriculture Appropriations bills, H.R. 5961/S. 2976). Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268). Support maintaining the Prevention and Public Health Fund (PPHF). Advocate for The National Hansens Disease Program funding in FY19 Labor/HHS/Education Appropriations (House Bill TBD, S. 3158). Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration in FY19 Labor/HHS/Education Appropriations (House Bill TBD, S. 3158). Support funding for Directed Medical Research Programs (CDMRP) at the Department of Defense (DoD) in the Fiscal Year 2019 (FY19) Defense Appropriations bill (H.R. 6157, S. 3159).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support H. Res. 282 to encourage proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Restoring Patients Voice Act. Support H.R. 1316, Prescription Drug Price Transparency Act. Support H.R. 2051, Fair Access for Safe and Timely Generics Act. Support H.R. 2212/S. 974, Creating and Restoring Equal Access to Equivalent Samples Act. Support H.R. 2999, Patients Access to Treatments Act. Support H.R. 3928, the Truth in Healthcare Marketing Act of 2017. Support S. 637, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act Support S. 2553, Know the Lowest Prices Act Support S. 2554, Patient Right to Know Drug Prices Act Support H.R. 5958, Phair Pricing Act Advocate for relief for from pior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 4841/H.R. 5773/Section 6062 of H.R. 6 (SUPPORT for Patients & Communities Act), Standardizing Electronic Prior Authorization for Safe Prescribing Act and S. 2908, Electronic Prior Authorization in Medicare Part D Act Support sunscreen related provisions in S. 2315, OTC Drug Safety, Innovation & Reform Act/H.R. 5333, OTC Monograph Safety, Innovation, & Reform Act Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for access to dermatological procedures for veterans through the Veterans Choice Program. Advocate for the continued funding of Community Health Centers.
Advocate against H.R. 1150, the Tanning Tax Repeal Act of 2017, and S. 2600, the Tanning Tax Repeal act of 2018, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.85/H.R. 394, Restoring Access to Medication Act).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 1316, Prescription Drug Price Transparency Act Support S. 637, C-THRU Act. Support S. 2553, Know the Lowest Price Act Support S. 2554, Patient Right to Know Drug Prices Act Support H.R. 5958, Phair Pricing Act Support sunscreen related provisions in S. 2315, OTC Drug Safety, Innovation & Reform Act/H.R. 5333, OTC Monograph Safety, Innovation, & Reform Act
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Support provisions to allow Medicare Advantage plans to include telehealth as a benefit. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 4206/S.2051 Medicare Care Coordination Improvement Act of 2017 Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Oppose elimination of a Merit-Based Incentive Payment System. Advocate allowing further appeals process within the Quality Payment Program. Advocate against H.R. 2066, Promoting Integrity in Medicare Act of 2017. Advocate for relief for from pior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 4841/H.R. 5773/Section 6062 of H.R. 6 (SUPPORT for Patients & Communities Act), Standardizing Electronic Prior Authorization for Safe Prescribing Act and S. 2908, Electronic Prior Authorization in Medicare Part D Act Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Support S. 2553, Know the Lowest Price Act. Lobby for support of nomination of Michael Bigby, MD to serve as Commissioner on Medicare Payment Advisory Commission (MedPAC).
Advocate for legislation to enact medical liability reforms. Support H.R. 1704, Accessible Care by Curbing Excessive lawSuitS (ACCESS) Act. Support H.R. 1215, Protecting Access to Care Act. Support H.R. 1876, Good Samaritans Health Professionals Act
Support legislation, such as, S. 1615/ H.R. 3440 DREAM Act, which would enable those individuals eligible with Deferred Action for Childhood Arrivals status are able to continue their employment, education, training, and research.
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program (H.R. 4242/S. 2193), included in the VA Mission Act (H.R. 5674/S. 2372).
Support funding for Directed Medical Research Programs (CDMRP) at the Department of Defense (DoD) in the Fiscal Year 2019 (FY19) Defense Appropriations bill (H.R. 6157, S. 3159).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, SENATE
Advocate against H.R. 1150, the Tanning Tax Repeal Act of 2017, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.85/H.R. 394, Restoring Access to Medication Act).
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 3268/S. 1603). Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268). Supported H. Res. 495, recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month". Support maintaining the Prevention and Public Health Fund (PPHF). Advocate for The National Hansens Disease Program funding in H.R. 1628, Consolidated Appropriations Act, 2018. Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration in FY19 Labor/HHS/Education Appropriations (Bill TBD) Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (H.R. 1628, Consolidated Appropriations Act, 2018) Support maintaining the Prevention and Public Health Fund (PPHF); opposed provisions to reducing PPHF in H.R.1892.
Support legislation, such as, S. 1615/ H.R. 3440 DREAM Act, which would enable those individuals eligible with Deferred Action for Childhood Arrivals status are able to continue their employment, education, training, and research.
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program (H.R. 4242/S. 2193).
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Support legislation to eliminate the Independent Payment Advisory Board (H.R. 849, Protecting Seniors Access to Medicare Act, , S.251, Protecting Medicare from Executive Action Act, S. 260, Protecting Seniors Access to Medicare Act) Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS) in the Bipartisan Budget Act of 2018, HR. 1892. Advocate for the expansion of telehealth coverage under Medicare Advantage Plan B, beginning in 2020 in the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for the repeal of the Independent Payment Advisory Board (IPAB) as part of the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for the elimination of the requirement that make electronic health record (EHR) meaningful use (MU) standards more stringent over time as part of the Bipartisan Budget Act of 2018, H.R. 1892. Oppose extension of the Medicare misvalued codes policy as part of the Bipartisan Budget Act of 2018, H.R. 1892. Oppose extension of 2 percent sequestration cuts to Medicare through 2027 as part of the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Support H.R. 2556/ S. 1016, CONNECT for Health Act of 2017. Lobby members of Congress regarding issues related to telemedicine and Medicare reimbursement, including regarding provisions in H.R. 2556/S.1016, CONNECT for Health Act of 2017 and S. 2870, Creating High-Quality Results and Outcomes Necessary to Improve (CHRONIC) Care Act of 2017. Support provisions to allow Medicare Advantage plans to include telehealth as a benefit. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 4206/S.2051 Medicare Care Coordination Improvement Act of 2017 Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Oppose elimination of a Merit-Based Incentive Payment System. Advocate allowing further appeals process within the Quality Payment Program. Advocate against H.R. 2066, Promoting Integrity in Medicare Act of 2017. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Support S. 2553, Know the Lowest Price Act. Lobby for support of nomination of Michael Bigby, MD to serve as Commissioner on Medicare Payment Advisory Commission (MedPAC).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 1316, Prescription Drug Price Transparency Act Support S. 637, C-THRU Act. Support S. 2553, Know the Lowest Price Act Support S. 2554, Patient Right to Know Drug Prices Act Support sunscreen related provisions in S. 2315, OTC Drug Safety, Innovation & Reform Act/H.R. 5333, OTC Monograph Safety, Innovation, & Reform Act
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support H. Res. 282 to encourage proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Restoring Patients Voice Act. Support H.R. 1316, Prescription Drug Price Transparency Act. Support H.R. 2051, Fair Access for Safe and Timely Generics Act. Support H.R. 2212/S. 974, Creating and Restoring Equal Access to Equivalent Samples Act. Support H.R. 2999, Patients Access to Treatments Act. Support H.R. 3928, the Truth in Healthcare Marketing Act of 2017. Support S. 637, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act Support S. 2553, Know the Lowest Prices Act Support S. 2554, Patient Right to Know Drug Prices Act Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act Support sunscreen related provisions in S. 2315, OTC Drug Safety, Innovation & Reform Act/H.R. 5333, OTC Monograph Safety, Innovation, & Reform Act Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for access to dermatological procedures for veterans through the Veterans Choice Program. Advocate for the continued funding of Community Health Centers. Advocate for funding the Community Health Center Fund in 2018 and 2019 in the Bipartisan Budget Act of 2018, H.R. 1892. Support maintaining the Prevention and Public Health Fund (PPHF); opposed provisions to reducing PPHF in H.R.1892.
Advocate for legislation to enact medical liability reforms. Support H.R. 1704, Accessible Care by Curbing Excessive lawSuitS (ACCESS) Act. Support H.R. 1215, Protecting Access to Care Act. Support H.R. 1876, Good Samaritans Health Professionals Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Advocate for legislation to enact medical liability reforms. Support H.R. 1704, Accessible Care by Curbing Excessive lawSuitS (ACCESS) Act. Support H.R. 1215, Protecting Access to Care Act. Support H.R. 1876, Good Samaritans Health Professionals Act
Support legislation, such as, S. 1615/ H.R. 3440 DREAM Act, which would enable those individuals eligible with Deferred Action for Childhood Arrivals status are able to continue their employment, education, training, and research.
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 3268/S. 1603). Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268). Supported H. Res. 495, recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month". Support maintaining the Prevention and Public Health Fund (PPHF). Advocate for The National Hansens Disease Program funding in H.R. 1628, Consolidated Appropriations Act, 2018. Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration in FY19 Labor/HHS/Education Appropriations (Bill TBD) Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (H.R. 1628, Consolidated Appropriations Act, 2018) Support maintaining the Prevention and Public Health Fund (PPHF); opposed provisions to reducing PPHF in H.R.1892.
Advocate against H.R. 1150, the Tanning Tax Repeal Act of 2017, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.85/H.R. 394, Restoring Access to Medication Act).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased transparency regarding drug pricing. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to support H. Res. 282 to encourage proper sun safety practices for youth under care of schools and camps. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 2077, Restoring Patients Voice Act. Support H.R. 1316, Prescription Drug Price Transparency Act. Support H.R. 2051, Fair Access for Safe and Timely Generics Act. Support H.R. 2212/S. 974, Creating and Restoring Equal Access to Equivalent Samples Act. Support H.R. 2999, Patients Access to Treatments Act. Support H.R. 3928, the Truth in Healthcare Marketing Act of 2017. Support S. 637, C-THRU Act. Support S. 989, Ensuring Childrens Access to Specialty Care Act Support S. 2553, Know the Lowest Prices Act Support S. 2554, Patient Right to Know Drug Prices Act Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act Support sunscreen related provisions in S. 2315, OTC Drug Safety, Innovation & Reform Act/H.R. 5333, OTC Monograph Safety, Innovation, & Reform Act Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs. Advocate for access to dermatological procedures for veterans through the Veterans Choice Program. Advocate for the continued funding of Community Health Centers. Advocate for funding the Community Health Center Fund in 2018 and 2019 in the Bipartisan Budget Act of 2018, H.R. 1892. Support maintaining the Prevention and Public Health Fund (PPHF); opposed provisions to reducing PPHF in H.R.1892.
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Support legislation to eliminate the Independent Payment Advisory Board (H.R. 849, Protecting Seniors Access to Medicare Act, , S.251, Protecting Medicare from Executive Action Act, S. 260, Protecting Seniors Access to Medicare Act) Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS) in the Bipartisan Budget Act of 2018, HR. 1892. Advocate for the expansion of telehealth coverage under Medicare Advantage Plan B, beginning in 2020 in the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for the repeal of the Independent Payment Advisory Board (IPAB) as part of the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for the elimination of the requirement that make electronic health record (EHR) meaningful use (MU) standards more stringent over time as part of the Bipartisan Budget Act of 2018, H.R. 1892. Oppose extension of the Medicare misvalued codes policy as part of the Bipartisan Budget Act of 2018, H.R. 1892. Oppose extension of 2 percent sequestration cuts to Medicare through 2027 as part of the Bipartisan Budget Act of 2018, H.R. 1892. Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Support H.R. 2556/ S. 1016, CONNECT for Health Act of 2017. Lobby members of Congress regarding issues related to telemedicine and Medicare reimbursement, including regarding provisions in H.R. 2556/S.1016, CONNECT for Health Act of 2017 and S. 2870, Creating High-Quality Results and Outcomes Necessary to Improve (CHRONIC) Care Act of 2017. Support provisions to allow Medicare Advantage plans to include telehealth as a benefit. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Support H.R. 4206/S.2051 Medicare Care Coordination Improvement Act of 2017 Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Oppose elimination of a Merit-Based Incentive Payment System. Advocate allowing further appeals process within the Quality Payment Program. Advocate against H.R. 2066, Promoting Integrity in Medicare Act of 2017. Advocate for relief for from prior authorization requirements under Medicare Advantage and Medicare Part D plans. Support H.R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs). Support S. 2553, Know the Lowest Price Act.
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 1316, Prescription Drug Price Transparency Act Support S. 637, C-THRU Act. Support S. 2553, Know the Lowest Price Act Support S. 2554, Patient Right to Know Drug Prices Act Support sunscreen related provisions in S. 2315, OTC Drug Safety, Innovation & Reform Act/H.R. 5333, OTC Monograph Safety, Innovation, & Reform Act
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program (H.R. 4242/S. 2193).
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program (H.R. 4242/S. 2193).
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Support legislation to eliminate the Independent Payment Advisory Board (H.R. 849, Protecting Seniors Access to Medicare Act, H.J. Res. 51, S.251, Protecting Medicare from Executive Action Act, S. 260, Protecting Seniors Access to Medicare Act, S.J. Res. 16 and S.J. Res. 17) Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Support H.R. 2556/ S. 1016, CONNECT for Health Act of 2017. Lobby members of Congress regarding issues related to telemedicine and Medicare reimbursement, including regarding provisions in H.R. 2556/S.1016, CONNECT for Health Act of 2017 and S. 2870, Creating High-Quality Results and Outcomes Necessary to Improve (CHRONIC) Care Act of 2017. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate allowing further appeals process within the Quality Payment Program. Advocate against H.R. 2066, Promoting Integrity in Medicare Act of 2017. Advocate for reform of insurers prior authorization practices within Medicare Advantage and Medicare prescription drug plans (Medicare Parts C and D). Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs).
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 3268/S. 1603). Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268). Supported H. Res. 495, recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month". Support maintaining the Prevention and Public Health Fund (PPHF).
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 1316, Prescription Drug Price Transparency Act Support S. 637, C-THRU Act.
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 36268/S. 1603). Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268).
Support legislation, such as, S. 1615/ H.R. 3440 DREAM Act, which would enable those individuals eligible with Deferred Action for Childhood Arrivals status are able to continue their employment, education, training, and research.
Advocate against the inclusion of any provisions to repeal the tanning tax provision under H.R. 1 or any other legislation. Advocate against H.R. 1150, the Tanning Tax Repeal Act of 2017, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.85/H.R. 394, Restoring Access to Medication Act). Educate members of the potential impact to physician practices which are structured as pass-through entities regarding provisions in H.R. 1.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 3628/S. 1603). Educate members of Congress regarding Carter Amendment (#7) to Division B of Rules Committee Print 115-31 related to access to compounded medications (H.R. 3628, FY 18 Agriculture Appropriations Bill). Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3628).
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 3628/S. 1603). Educate members of Congress regarding Carter Amendment (#7) to Division B of Rules Committee Print 115-31 related to access to compounded medications (H.R. 3628, FY 18 Agriculture Appropriations Bill). Advocate for the inclusion of Congressional Directed Medical Research Programs in the 2018 National Defense Authorization Act (S. 1519/H.R. 2810). Advocate against Sections 733, 891, 892, and 893 in S. 1519, which would impact CDMRP. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3628). Supported H. Res. 495, recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month". Support maintaining the Prevention and Public Health Fund (PPHF); opposed provisions to repeal the PHHF in H.R. 1628 (American Health Care Act/Better Care Reconciliation Act).
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Support legislation to eliminate the Independent Payment Advisory Board (H.R. 849, Protecting Seniors Access to Medicare Act, H.J. Res. 51, S.251, Protecting Medicare from Executive Action Act, S. 260, Protecting Seniors Access to Medicare Act, S.J. Res. 16 and S.J. Res. 17) Advocate for increased funding and reforms to Graduate Medical Education. Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration. Lobby members of Congress regarding improvements to Health Information Technology implementation. Support H.R. 2556/ S. 1016, CONNECT for Health Act of 2017. Lobby members of Congress regarding issues related to telemedicine and Medicare reimbursement, including regarding provisions in H.R. 2556/S.1016, CONNECT for Health Act of 2017 and S. 2870, Creating High-Quality Results and Outcomes Necessary to Improve (CHRONIC) Care Act of 2017. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110) Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate allowing further appeals process within the Quality Payment Program. Advocate against H.R. 2066, Promoting Integrity in Medicare Act of 2017. Advocate for reform of insurers prior authorization practices within Medicare Advantage and Medicare prescription drug plans (Medicare Parts C and D). Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs).
Advocate for legislation to enact medical liability reforms. Support H.R. 1704, Accessible Care by Curbing Excessive lawSuitS (ACCESS) Act. Support H.R. 1215, Protecting Access to Care Act.
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription. Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting. Support H.R. 2871, Preserving Patient Access to Compounded Medications Act. Support H.R. 1316, Prescription Drug Price Transparency Act Support S. 637, C-THRU Act.
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program.
Support legislation, such as, S. 1615/ H.R. 3440 DREAM Act, which would enable those individuals eligible with Deferred Action for Childhood Arrivals status are able to continue their employment, education, training, and research.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Advocate against the repeal of the tanning tax provision under the Better Care Reconciliation Act of 2017 (H.R. 1628). Advocate against H.R. 1150, the Tanning Tax Repeal Act of 2017, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.85/H.R. 394, Restoring Access to Medication Act).
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage. Support legislation to eliminate the Independent Payment Advisory Board (H.R. 849, Protecting Seniors Access to Medicare Act, H.J. Res. 51, S.251, Protecting Medicare from Executive Action Act, S. 260, Protecting Seniors Access to Medicare Act, S.J. Res. 16 and S.J. Res. 17) Advocate for increased funding and reforms to Graduate Medical Education. Lobby members of Congress regarding improvements to Health Information Technology implementation. Lobby members of Congress regarding issues related to telemedicine and Medicare reimbursement, including regarding provisions in H.R. 2556, S. 1016, Connect for Health Act of 2017. Advocate for improving disease management and care coordination for patients with chronic diseases. Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception. Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (P.L. 114-110). Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS). Advocate against H.R. 2066, Promoting Integrity in Medicare Act of 2017. Advocate for reform of insurers prior authorization practices.
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 17 & 18 Labor/HHS/Education Appropriations and FY 17 & 18 Agriculture Appropriations bills, H.R. 244). Oppose report language calling on the Centers for Disease Control to commission the National Academy of Science to study the efficacy and health benefits of vitamin D supplements vs. Non-burning Sunshine (FY 17 & 18 Labor/HHS/Education Appropriations and FY 17 & 18 Agriculture Appropriations bills, H.R. 244)
Advocate for legislation to enact medical liability reforms. Support H.R. 1704, Accessible Care by Curbing Excessive lawSuitS (ACCESS) Act. Support H.R. 1215, Protecting Access to Care Act.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Advocate against the repeal of the tanning tax provision under the American Health Care Act of 2017 (H.R. 1628). Advocate against H.R. 1150, the Tanning Tax Repeal Act of 2017, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.85/H.R. 394, Restoring Access to Medication Act).
Advocate for legislation to enact medical liability reforms.
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 17 & 18 Labor/HHS/Education Appropriations and FY 17 & 18 Agriculture Appropriations bills).
Lobby members of the House to write to FDA regarding the agencys draft guidance document on office-use compounding. Support H.R. 4784, the Lower Drug Costs through Competition Act. Lobby members of the House to join the Congressional Skin Cancer Caucus. Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act, intended to protect and preserve the in-office use of compounded pharmaceuticals without a patient prescription. Lobby members of Congress regarding issues related to telemedicine. Advocate for increased price transparency for drugs and tools to help lower costs. Advocate for the sense of Congress that states should expand access to sun safety products and practices. Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Advocate for legislation to enact medical liability reforms.
Advocate against H.R. 2698, the Tanning Tax Repeal Act of 2015, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S. 709, H.R. 1270, Restoring Access to Medication Act). Support legislation that would increase pre-tax savings for Flexible Spending Accounts and allow funds to be carried over from year to year in perpetuity (H.R. 1185/S. 3242, The Responsible Additions and Increases to Sustain Employee Health Benefits Act of 2015).
Support H.R. 6/H.R. 34, the 21st Century Cures Act to strengthen and improve the discovery, development and delivery of treatments and cures. Advocate for NIH and FDA reforms in the Innovation for Healthier Americans initiative. Advocate for medical research, education and prevention funding at the National Institutes of Health, National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality under the Labor, Health and Human Services, and Education Appropriations legislation (S.3040 and H.R. 5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017). Oppose report language calling on the Centers for Disease Control to commission the National Academy of Science to study the efficacy and health benefits of vitamin D supplements vs. Non-burning Sunshine (H.R. 5926 and S. 3040, Departments of Labor Health and Human Services and Education, and Related Agencies Appropriations Act, 2017). Advocate regarding proposed indoor tanning regulations and report language regarding access to compounded pharmaceuticals under the Senate and House Agriculture Appropriations bills (S.2956/H.R.5054, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017). Advocate for funding of the Peer Reviewed Cancer Research Program in the Department of Defense Appropriations Act of 2017 (S. 3000 and H.R. 5293).
Advocate regarding proposed regulations under Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10). Advocate against CMS proposal regarding collection of data for all 10- and 90- day global surgery services. Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage and health insurance exchange networks (S. 2392 / H.R. 4227, the Medicare Advantage Bill of Rights Act of 2015). Support legislation to eliminate the Independent Payment Advisory Board (S.141/ H.R. 1190, Protecting Seniors' Access to Medicare Act of 2015). Lobby Congress on improvements to Health Information Technology implementation. Lobby Congress on issues related to telemedicine and Medicare reimbursement. Support legislation to have telemedicine services reimbursable by Medicare (S. 2484/ H.R. 4442, the Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act). Advocate on use and availability of health care data. Lobby in support of legislation to provide more flexibility in the Meaningful Use program (H.R. 3309, the Further Flexibility in HIT Reporting and Advancing Interoperability (Flex IT 2) Act). Advocate for EHR interoperability and enhancements to the federal certification system for health information technology; advocate for provisions to restrict data blocking by Electronic Health Records vendors (S. 2141, Transparent Ratings on Usability & Security to Transform Technology Act of 2015, S.2511, Improving Health Information Technology Act and H.R. 6/H.R. 34, 21st Century Cures Act). Advocate for improving disease management and care coordination for patients with chronic diseases (H.R. 6/H.R. 34, 21st Century Cures Act). Support preservation of the In-Offices Ancillary Services Exemption under Stark Law regarding physician self-referral. Advocate against H.R. 5008, Promoting Integrity in Medicare Act of 2016 Support legislation to provide more flexibility in compliance with the Sunshine Act (S.2978). Support legislation to have telemedicine services reimbursable by Medicare (S. 2484/H.R. 4442, the Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act). Support S. 2978, Protecting Continuing Physician Education & Patient Care Act. Advocate for increased graduate medical education funding.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
Support H.R. 6, the 21st Century Cures Act to strengthen and improve the discovery, development and delivery of treatments and cures. Advocate for NIH and FDA reforms in the Innovation for Healthier Americans initiative. Advocate for medical research, education and prevention funding at the National Institutes of Health, National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality under the Labor, Health and Human Services, and Education Appropriations legislation (S.3040 and H.R. 5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017). Oppose report language calling on the Centers for Disease Control to commission the National Academy of Sciences to study the efficacy and health benefits of vitamin D supplements vs Non-burning Sunshine (S.3040 and H.R. 5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017) Advocate regarding proposed indoor tanning regulations and report language regarding access to compounded pharmaceuticals under the Senate and House Agriculture Appropriations bills (S.2956/H.R.5054, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017).
Advocate against H.R. 2698, the Tanning Tax Repeal Act of 2015, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S. 709, H.R. 1270, Restoring Access to Medication Act). Support legislation that would increase pre-tax savings for Flexible Spending Accounts and allow funds to be carried over from year to year in perpetuity (H.R. 1185/S.3242 The Responsible Additions and Increases to Sustain Employee Health Benefits Act of 2015)
Advocate for legislation to enact medical liability reforms.
Advocate regarding proposed regulations under Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10). Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage and health insurance exchange networks (S. 2392 / H.R. 4227, the Medicare Advantage Bill of Rights Act of 2015). Support legislation to eliminate the Independent Payment Advisory Board (S.141/ H.R. 1190, Protecting Seniors' Access to Medicare Act of 2015). Lobby Congress on improvements to Health Information Technology implementation. Lobby Congress on issues related to telemedicine and Medicare reimbursement. Support legislation to have telemedicine services reimbursable by Medicare (S. 2484/ H.R. 4442, the Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act). Advocate on use and availability of health care data. Lobby in support of legislation to provide more flexibility in the Meaningful Use program (, H.R. 3309, the Further Flexibility in HIT Reporting and Advancing Interoperability (Flex IT 2) Act), H.R. 3940, HR 5001/S.2822 Flexibility in Electronic Health Record Reporting Act. Advocate for EHR interoperability and enhancements to the federal certification system for health information technology (S. 2141, Transparent Ratings on Usability & Security to Transform Technology Act of 2015 and S.2511, Improving Health Information Technology Act). Lobby in support of legislation to require the Secretary of Health and Human Services to issue guidance on the application of the Common Rule to clinical data registries (H.R. 965, Facilitating Participation in Clinical Data Registries Act of 2015). Support legislation to reduce Medicare fraud and improve access to Death Master File, S. 1073, the Stopping Improper Payments to Deceased People Act. Advocate for improving disease management and care coordination for patients with chronic diseases Support preservation of the In Offices Ancillary Services Exemption under Stark Law regarding physician self-referral. Advocate against H.R. 5008, Promoting Integrity in Medicare Act of 2016 Support legislation to provide more flexibility in compliance with the Sunshine Act (S.2978). Advocate against data blocking by Electronic Health Records vendors. Support legislation to have telemedicine services reimbursable by Medicare (S. 2484/H.R. 4442, the Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act). Support S. 2978, Protecting Continuing Physician Education & Patient Care Act. Advocate for increased graduate medical education funding. Lobby members of House to write to CMS in opposition of a policy in the 2017 Medicare Physician Fee Schedule Proposed Rule that would require all physicians to collect and report data on all services included in 10- and 90-day global surgery codes.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Advocate for improved access to specialty drugs for patients with chronic conditions (H.R. 1600, Patients' Access to Treatments Act of 2015). Support S. 1406, the Saving Access to Compounded Medications for Special Needs Patients Act. Lobby members of House to write to FDA regarding the agencys draft guidance document on office-use compounding Support S. 2615, the Increasing Competition in Pharmaceuticals Act Lobby members of Congress to join the Congressional Skin Cancer Caucus. Lobby Congress to provide oversight of implementation of Public Law 113-54, the Drug Quality and Security Act, and to protect and preserve the in-office use of compounded pharmaceuticals without a patient prescription. Lobby members of House and Senate to send letters of support to FDA regarding the agencys proposed rule to restrict indoor tanning for youth under 18. Lobby Congress on issues related to telemedicine. Support legislation to establish a federal standard for the provision of telemedicine (H.R. 691, the Telehealth Modernization Act). Oppose S.2175, Department of Veterans Affairs Provider Equity Act. Advocate for increased price transparency for drugs and tools to help lower costs. Advocate for Ensuring Childrens Access to Specialty Care Act (H.R. 1859/S. 2782). Advocate regarding proposed indoor tanning regulations and provisions regarding compounded pharmaceuticals under the Senate and House Agriculture Appropriations bills (S.2956/H.R.5054, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017).
Advocate against H.R. 2698, the Tanning Tax Repeal Act of 2015, to repeal excise tax on indoor tanning services. Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S. 709, H.R. 1270, Restoring Access to Medication Act).
Advocate for legislation to enact medical liability reforms.
Advocate regarding proposed regulations under Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10). Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage and health insurance exchange networks (S. 2392 / H.R. 4227, the Medicare Advantage Bill of Rights Act of 2015). Support legislation to eliminate the Independent Payment Advisory Board (S.141/ H.R. 1190, Protecting Seniors' Access to Medicare Act of 2015). Lobby Congress on improvements to Health Information Technology implementation. Lobby Congress on issues related to telemedicine and Medicare reimbursement. Advocate on use and availability of health care data. Lobby in support of legislation to provide more flexibility in the Meaningful Use program (, H.R. 3309, the Further Flexibility in HIT Reporting and Advancing Interoperability (Flex IT 2) Act), H.R. 3940, HR 5001/S.2822 Flexibility in Electronic Health Record Reporting Act. Advocate for EHR interoperability and enhancements to the federal certification system for health information technology (S. 2141, Transparent Ratings on Usability & Security to Transform Technology Act of 2015 and S.2511, Improving Health Information Technology Act). Lobby in support of legislation to require the Secretary of Health and Human Services to issue guidance on the application of the Common Rule to clinical data registries (H.R. 965, Facilitating Participation in Clinical Data Registries Act of 2015). Support legislation to improve transparency and due process in the Medicare RAC audit and appeals process (H.R. 2568, Fair Medical Audits Act). Support legislation to reduce Medicare fraud and improve access to Death Master File, S. 1073, the Stopping Improper Payments to Deceased People Act. Advocate for improving disease management and care coordination for patients with chronic diseases Support preservation of the In Offices Ancillary Services Exemption under Stark Law regarding physician self-referral. Advocate against H.R. 5008, Promoting Integrity in Medicare Act of 2016 Support legislation to provide more flexibility in compliance with the Sunshine Act (S.2978). Advocate against data blocking by Electronic Health Records vendors. Support legislation to have telemedicine services reimbursable by Medicare (S. 2484/ H.R. 4442, the Creating Opportunities Now for Necessary and Effective Care Technologies for Health Act). Support S. 2978, Protecting Continuing Physician Education & Patient Care Act. Advocate for increased graduate medical education funding.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Advocate for improved access to specialty drugs for patients with chronic conditions (H.R. 1600, Patients' Access to Treatments Act of 2015). Support S. 1406, the Saving Access to Compounded Medications for Special Needs Patients Act. Support S. 2615, the Increasing Competition in Pharmaceuticals Act Lobby members of Congress to join the Congressional Skin Cancer Caucus. Lobby Congress to provide oversight of implementation of Public Law 113-54, the Drug Quality and Security Act, intended to protect and preserve the in-office use of compounded pharmaceuticals without a patient prescription. Lobby members of House and Senate to send letters of support to FDA regarding the agencys proposed rule to restrict indoor tanning for youth under 18. Advocate members of Congress for oversight of implementation of Sunscreen Innovation Act. Lobby Congress on issues related to telemedicine. Support legislation to establish a federal standard for the provision of telemedicine (H.R. 691, the Telehealth Modernization Act). Support S.2175, Department of Veterans Affairs Provider Equity Act. Advocate for increased price transparency for drugs and tools to help lower costs.
Support H.R. 6, the 21st Century Cures Act to strengthen and improve the discovery, development and delivery of treatments and cures Advocate for NIH and FDA reforms in the Innovation for Healthier Americans initiative. Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 17 Labor/HHS/Education Appropriations and FY 17 Agriculture Appropriations bills). Support legislation to adjust discretionary spending caps for biomedical research (S. 318/H.R. 531, Accelerating Biomedical Research Act; S. 289, American Cures Act)
Advocate for legislation to enact medical liability reforms.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE